Cutaneous leishmaniasis is caused by different species of the genus *Leishmania*, and the estimated number of new cases annually is around 1.1 million ([@CIT0001], [@CIT0002]). In Latin America with the exception of Chile and Antilles, 638,702 cases were reported in the period 2001--2011 ([@CIT0003]). Cutaneous leishmaniasis results from multiplication of *Leishmania* in the phagocytes of the skin ([@CIT0004]). In Bolivia, most cases are caused by *Leishmania* (*Viannia*) *braziliensis* ([@CIT0005], [@CIT0006]). The cases are characterized by one or more lesions with raised borders often associated with secondary bacterial infection and frequently localized in the exposed areas of the skin ([@CIT0007]--[@CIT0009]).

Among malnutrition conditions, micronutrient deficiencies can contribute to the exacerbation and delayed recovery of infectious and chronic non-infectious diseases ([@CIT0010], [@CIT0011]). In human cutaneous leishmaniasis, a significant decrease of zinc concentration and increase of copper concentration in plasma have been demonstrated which may be associated with the inability of the host to kill the parasites or be an indication of the inflammatory process ([@CIT0012], [@CIT0013]). Other aspects of the biochemical nutritional status in leishmaniasis have not been studied previously. In Bolivia, no data regarding the prevalence of micronutrient deficiencies in the general population is available. Regarding therapy for cutaneous leishmaniasis, the systemic use of antimony compounds gives a cure rate of 77--90% ([@CIT0001]). The results of oral zinc treatment studies in cutaneous leishmaniasis have been contradictory. A decrease of erythemas and size of the induration was reported ([@CIT0014], [@CIT0015]) but others found no effect of zinc on cutaneous leishmaniasis ([@CIT0016]). Still the available data on the effects of zinc as nutritional supplementation in this disease are scant.

In the present study, we compared biochemical nutritional status in cutaneous leishmaniasis patients and matched controls and conducted a placebo-controlled study on the effect of zinc supplementation in patients with cutaneous leishmaniasis.

Methods {#S0002}
=======

Patients {#S0002-S20001}
--------

The patients were residents of the Isiboro--Sécure national park, a tropical forest of Cochabamba province. The patients were selected on the basis of the following criteria: age 15--50 years, diagnosis of cutaneous leishmaniasis by any of the two laboratory tests described below, and no history of previous leishmaniasis episodes. Exclusion criteria were mucosal or mucocutaneous leishmaniasis, presence of more than two cutaneous lesions, pregnancy, lactation, use of nutritional supplements, presence of diabetes mellitus, chronic renal failure, or liver disease. We contacted 87 patients with cutaneous leishmaniasis visiting Villa Tunari Hospital and the 34 patients meeting the inclusion criteria were selected. All patients completed a health questionnaire prior to entering the study and signed a consent form for inclusion into the study.

Control subjects {#S0002-S20002}
----------------

The controls were age- and gender-matched subjects living in the same area as the corresponding patients. All controls completed a health questionnaire prior to entering the study and signed a consent form for inclusion into the study. Subjects were excluded if they had diabetes mellitus, had cardiovascular disease, were in pregnancy or lactation, or received regular medication or nutritional supplements.

Zinc supplementation and antimony treatment of cutaneous leishmaniasis {#S0002-S20003}
----------------------------------------------------------------------

Patients were randomly allocated to receive zinc or placebo coded capsules for 60 days. Each zinc capsule contained 315 mg of zinc gluconate (45 mg zinc) and each placebo capsule contained 315 mg of corn starch (Farmacia artesanal, Cochabamba, Bolivia). One capsule per day (zinc or placebo) was taken after a meal coinciding with the time of antimony injection during the therapy period and continued at the same time thereafter. All patients received for 20 days daily intramuscular injections of pentavalent antimony (Glucantime^®^, Sanofi Aventis Farmacêutica Ltda, São Paulo, Brazil), 20 mg Sb/kg/day. The physicians in the health care centers of Isiboro-Sécure park administered the injection. The compliance was assessed by daily reporting of given capsule by the physicians. Control subjects were not given any drugs or capsules.

Materials and measurements {#S0002-S20004}
--------------------------

Venous blood collection tubes of the Vacutainer^®^ system (cat no 367874 and 368380) were obtained from Becton Dickinson AB (Stockholm, Sweden). Blood agar No2 (cat no DF 0027-17-0) was obtained from Difco Laboratories Inc (Detroit, Michigan, USA). The Panotic fast staining system (cat no 620529) was obtained from LB (Laborclin, São Paulo, Brazil) and disposable plastic calipers for the measurement of lesion dimensions were obtained in local commerce.

Collection of blood samples {#S0002-S20005}
---------------------------

For patients, blood was sampled three times, before the start of the treatment (T0), after 20 days at the end of antimony treatment (T1) and after 60 days of supplementation with zinc or placebo (T2). For controls, blood was sampled at time zero only. Blood was collected by venipuncture after 12 h of fasting and 30 min of relaxation between 7 and 8 in the morning into polystyrene test tubes. They were centrifuged for 10 min at ≥2,000 g and plasma samples were aliquoted and stored at −80°C until analysis.

Microbiological and biochemical analysis {#S0002-S20006}
----------------------------------------

Parasite identification was performed by microscopy of stained smears of scrapings of lesion borders and by isolation in culture ([@CIT0017]). Briefly, smears of scrapings of lesion borders in triplicate were stained with the Panotic fast system and microscopically assessed for amastigote forms of the parasite. The isolation by culture was performed by inoculation of aspirates into tubes containing blood agar base No2 and 10% rabbit defibrinated blood ([@CIT0018]). The tubes were incubated at 26°C for 10 days and the promastigote form of parasite was microscopically assessed. Total number of white blood cells, neutrophils, eosinophils and lymphocytes (as fraction of white blood cells), red blood cells, hemoglobin, and hematocrit were measured within 30 min after blood sampling using the Auto hematology analyzer BC-3000 Plus, Mindray™ (Nanshan, Shenzhen, China) at the Villa Tunari Hospital. ASAT, ALAT, urea, and glucose in serum were also measured by photometry. The transferrin receptor was measured by an ELISA test kit (R&D Systems) at the IIBISMED laboratories. The other clinical chemistry measurements were performed at the Clinical Chemistry Laboratory of Skåne University Hospital, Lund, Sweden, using certified methods. These data were compared with the reference ranges for healthy subjects established at that laboratory.

Assessment of lesion healing {#S0002-S20007}
----------------------------

The cutaneous lesions were assessed in two time phases, the first one at 3, 9, 15, and 20 days, concomitant with antimony treatment and then every 10 days during the last 40 days. Area of lesion (mm^2^) and presence of raised edge of lesion, inflammatory halo, satellite lesions, and purulent material were measured. The area was calculated using the formula for a circle or ellipse based on measurements with a caliper. The healing of lesions was expressed as percent reduction of the initial area.

Ethics permission {#S0002-S20008}
-----------------

Ethics permission for procedures involving human volunteers was obtained from the Bolivian Ethics Committee of the Medical Faculty, Universidad Mayor de San Simón and the Regional Ethics Committee, Lund, Sweden (no. 2009/171).

Statistical analysis {#S0002-S20009}
--------------------

The SPSS software was used. The Mann--Whitney test was used for testing the significance of differences between two non-normally distributed continuous variables for comparisons between patients and controls and also for two non-normally distributed quantitative discrete variables between zinc-supplemented and placebo groups. Chi-square analysis was used for comparison of individual characteristics of the lesions between the groups. The Wilcoxon signed rank test was used to compare the same variables of patients at T0, T2 and in controls for the two groups (zinc-supplemented or placebo). No corrections for multiple testing were made.

Results {#S0003}
=======

Comparison of nutritional status in patients and controls {#S0003-S20001}
---------------------------------------------------------

For patients and 29 matched controls there were no statistically significant differences in weight, height and body mass index (BMI) (Supplementary Table 1). The plasma concentrations of nutrient-related compounds ([Table 1](#T0001){ref-type="table"}) showed in both patient groups increased values of transferrin receptor at T0 compared with the corresponding controls (*p*=0.002 and 0.033, respectively). Still a concentration above the reference range was observed in only two female patients at T2. This can reflect depleted iron storage and the two patients had also subnormal concentrations of iron and ferritin in plasma and high values of the total iron-binding capacity and also low blood hemoglobin values both at T0 and T2. A slightly lower concentration of sodium at T0 in the placebo group compared to control was observed (*p*=0.05). For plasma vitamin B12, subnormal values were observed in five patients at T0 and also at T2 and in three controls but no significant differences between the group mean values were observed. For other nutrient-related compounds, there were no significant differences between patients at T0 and controls ([Table 1](#T0001){ref-type="table"}).

###### 

Plasma concentration of nutrient-related compounds in cutaneous leishmaniasis patients before and after zinc supplementation and in controls

                                                                       *p*                     
  -------------------------------- ----------- ----------- ----------- ------- ------- ------- -------
  Zinc group (*n*=14)                                                                          
   Vitamin B12 (pmol/L)            298 (131)   291 (105)   251 (68)    0.92    0.16    0.14    0.43
   Folate (nmol/L)                 19 (5)      15 (3)      15 (3)      0.004   0.12    0.82    0.023
   Cholesterol (mmol/L)            3.6 (0.8)   3.6 (0.7)   3.8 (0.5)   0.83    0.55    0.43    0.79
   Triglyceride (mmol/L)           0.9 (0.3)   0.9 (0.6)   1.1 (0.7)   0.47    0.97    0.87    0.36
   Calcium (mmol/L)                2.4 (0.1)   2.3 (0.1)   2.3 (0.1)   0.27    0.41    0.10    0.71
   Magnesium (mmol/L)              0.8 (0.1)   0.8 (0.1)   0.8 (0.1)   0.35    0.42    0.21    0.26
   Sodium (mmol/L)                 142 (2.5)   140 (4.0)   143 (2.4)   0.10    0.19    0.02    0.56
   Potassium (mmol/L)              3.9 (0.5)   4.1 (1.1)   4.5 (1.7)   0.98    0.30    0.68    0.91
   Phosphate (mmol/L)              1.6 (0.9)   1.6 (1.1)   1.5 (0.9)   0.93    0.77    0.97    0.33
   Iron (µmol/L)                   15 (6.3)    15 (7.0)    19 (9.0)    0.58    0.30    0.39    0.76
   Ferritin (µg/L)                 99 (145)    101 (131)   78 (43)     0.27    0.19    0.47    0.41
   Transferrin receptor (nmol/L)   16 (3.4)    18 (17.3)   12 (3.0)    0.15    0.002   0.17    0.019
   TIBC (µmol/L)                   71 (12)     66 (17)     71 (6)      0.11    0.83    0.22    0.60
  Placebo group (*n*=15)                                                                       
                                                                                               
   Vitamin B12 (pmol/L)            228 (87)    235 (82)    234 (75)    0.36    0.59    0.87    
   Folate (nmol/L)                 17 (5)      17 (4)      19 (5)      0.82    0.30    0.27    
   Cholesterol (mmol/L)            4.3 (1.2)   4.3 (1.1)   4.7 (1.2)   0.82    0.17    0.31    
   Triglyceride (mmol/L)           0.9 (0.3)   1.1 (0.4)   1.3 (0.7)   0.38    0.06    0.48    
   Calcium (mmol/L)                2.3 (0.1)   2.3 (0.1)   2.4 (0.1)   0.53    0.057   0.012   
   Magnesium (mmol/L)              0.8 (0.1)   0.8 (0.1)   0.8 (0.1)   0.80    0.23    0.19    
   Sodium (mmol/L)                 142 (3.2)   141 (5,1)   144 (3.5)   0.61    0.050   0.01    
   Potassium (mmol/L)              3.9 (0.7)   4.1 (0.9)   4.7 (1.7)   0.89    0.10    0.19    
   Phosphate (mmol/L)              1.7 (1.0)   1.3 (0.7)   1.8 (1.1)   0.14    0.86    0.08    
   Iron (µmol/L)                   15 (7.6)    15 (5.9)    18 (7.1)    0.91    0.43    0.31    
   Ferritin (µg/L)                 86 (120)    81 (91)     134 (126)   0.91    0.14    0.09    
   Transferrin receptor (nmol/L)   15 (5.5)    19 (11.8)   11 (3.1)    0.07    0.033   0.005   
   TIBC (µmol/L)                   71 (11)     68 (11)     71 (7.4)    0.16    0.86    0.28    

The data are expressed as mean (SD).

Ctrl, Control. TIBC, total iron-binding capacity.

Wilcoxon\'s signed-rank test, level of significance *p*\<0.05;

Mann--Whitney test, level of significance *p*\<0.05.

Clinical observations after zinc supplementation {#S0003-S20002}
------------------------------------------------

Thirty-four patients entered in the study and 29 completed it. The reasons for dropping out in the placebo group were low adherence to the supplementation and clinical follow-up in three cases and low adherence to the antimony treatment in one case. In the zinc-supplemented group one case dropped out due to low adherence to the clinical follow up. The time course for reduction of lesion area did not differ significantly between placebo and zinc-supplemented groups ([Fig. 1](#F0001){ref-type="fig"}). The differences in lesion area (%) were significant for the intervals day ([@CIT0009]--[@CIT0015]), ([@CIT0015]--[@CIT0020]), and ([@CIT0020]--[@CIT0030]) in both groups ([Table 2](#T0002){ref-type="table"}). Regarding the four lesion characteristics, a higher frequency of purulent material (an indicator of superinfection) and of inflammatory halo was found in the zinc-supplemented group at day 20 only (Chi-square test p≤0.05) ([Fig. 2](#F0002){ref-type="fig"}).

![Changes of the lesion area in patients with cutaneous leishmaniasis during the supplementation period with zinc or placebo. ^a^Before starting treatment, ^b^end of antimony therapy, ^c^end of supplementation period. Mann-Whitney test, *p*\>0.05 at all time points.](FNR-58-23353-g001){#F0001}

![Clinical characteristics of cutaneous leishmaniasis lesions in zinc or placebo supplemented groups (expressed as percent of occurrence).\
^a^Starting treatment, ^b^end of antimony therapy, ^c^end of supplementation period. Significant differences between groups at 20th day for purulent material and inflammatory halo (Chi-square test, *p*≤0.05).](FNR-58-23353-g002){#F0002}

###### 

The changes in lesion area in patients with cutaneous leishmaniasis as measured as differences of area between occasions of clinical observation in zinc-supplemented and placebo groups

           Differences in lesion area (mm^2^)   *p*                        
  -------- ------------------------------------ ---------- ------- ------- ------
  0--3     22.5 (143)                           0 (49)     0.72    0.50    0.59
  3--9     34 (155)                             35 (130)   0.65    0.023   0.62
  9--15    81 (192)                             22 (181)   0.017   0.009   0.72
  15--20   29.5 (93)                            9 (106)    0.003   0.012   0.38
  20--30   6.5 (73)                             3 (52)     0.012   0.043   0.51
  30--40   0 (12.5)                             0          0.71    0.18    0.65
  40--50   0 (44)                               0          0.06    0.31    0.56
  50--60   0                                    0          1.00    0.18    0.71

Data were expressed as median (IQR).

Wilcoxon\'s signed-rank test, level of significance *p*\<0.05,

Mann--Whitney test, level of significance *p*\<0.05.

Biochemical markers after zinc supplementation {#S0003-S20003}
----------------------------------------------

The number of red cells, hematocrit, and the hemoglobin concentration were decreased at T1 in both zinc-supplemented and placebo groups compared to data at T0 (Supplementary Table 2). The total number of leucocytes was lower in both groups at T0 and the fraction of lymphocytes was lower at T1 and T2 in the placebo group compared with the data in controls (Supplementary Table 2). The enzymes ASAT and ALAT tended to be higher at T1 than at T0 and T2 (Supplementary Table 3). These findings may partly indicate side effects of antimony treatment.

Regarding inflammatory markers (Supplementary Table 4), an increase of CRP at T2 compared to at T0 was found in the zinc-supplemented group together with a small decrease in the placebo group although without statistical significance in both cases. The concentration of haptoglobin was decreased at T2 compared to T0 in both zinc-supplemented and placebo groups. Orosomucoid was decreased in the placebo group at T2 compared to T0.

Regarding nutrient-related compounds ([Table 1](#T0001){ref-type="table"}), the concentration of folate was decreased at T2 compared to T0 in the zinc-supplemented group. At T2 the calcium concentration in the placebo group was decreased (*p*=0.012). The comparison of the differences T2--T0 between zinc-supplemented and placebo groups showed a significantly larger decrease of folate and smaller increase of transferrin receptor in the zinc-supplemented group compared with the placebo group.

Regarding other clinical chemistry biomarkers (Supplementary Table 5), decreased concentration of creatinine was found at T2 in the zinc-supplemented group compared with T0 (*p*=0.019). Regarding gammaglutamyltransferase (GT) only one patient had high values at T0 and T2 and also one control. Alkaline phosphatase (ALP) was slightly elevated in four patients at T0, nine patients at T2 and in seven controls. No differences were found between zinc-supplemented and placebo groups in these respects.

Discussion {#S0004}
==========

Nutritional status {#S0004-S20001}
------------------

Regarding general nutritional status in leishmaniasis, a low BMI (\<18.5 kg/m^2^) was found in 10% and hypoalbuminemia (\<35 g/L) in 12% of the patients ([@CIT0019]). In our patient group only one patient (of 29) has such a low BMI and three patients had a BMI below 20 kg/m^2^. Only one of our patients had a plasma albumin below 35 g/L. In another study, children with visceral leishmaniasis were found to have a lower BMI and plasma albumin than the other groups studied ([@CIT0020]). The loss of weight may be attributable in cases of American tegumentary leishmaniasis to difficulties to eat ([@CIT0019]) and in visceral leishmaniasis to the cachexia caused by the infection ([@CIT0020]).

Concerning the nutrient-related compounds of plasma, the concentration of transferrin receptor was higher in patients than in controls ([Table 1](#T0001){ref-type="table"}). Also low levels of plasma iron and high levels of iron-binding capacity were observed in several patients. The subnormal iron status can at least partly be explained by a sequestration of iron which can limit the leishmania infection ([@CIT0021]--[@CIT0023]). Other authors also reported decreased levels of iron plasma concentration in cutaneous and visceral leishmaniasis which was interpreted partly as a response to the effect of immunoregulatory cytokines ([@CIT0024], [@CIT0025]).

Zinc supplementation in leishmaniasis {#S0004-S20002}
-------------------------------------

This study explored the effects of zinc provided as a nutritional supplement in addition to antimony treatment on changes in lesions and biochemical markers in patients with cutaneous leishmaniasis. No additional effect of zinc on lesion healing was found which can be explained by the high efficacy of antimony alone. Previously oral zinc sulfate was studied as an anti-leishmania drug and the cure rates were 83.9, 93.1 and 96.9% with the doses of 2.5, 5 and 10 mg/kg/day, respectively ([@CIT0014]). A comparison of treatment by zinc sulfate (10 mg/kg/day) and the intramuscular antimony treatment (20 mg/kg/day) showed no difference in cure rates (30.2 and 35.5%, respectively) ([@CIT0016]). The dose of zinc used by us (45 mg/day) is close to 2.5 mg/kg/day of zinc sulfate (assuming that the latter was given as the heptahydrate). The present study seems to be the only one in which oral zinc as nutritional supplementation has been combined with intramuscular antimony injections. Zinc has also been used as intralesional treatment. Injection of 2% zinc sulfate, 7% sodium chloride or pentavalent antimony all gave cure rates of 85--95% ([@CIT0026]). In a similar study of intralesional injections zinc sulfate gave a cure rate of 83.8% and pentavalent antimony of 60% ([@CIT0027]). Other intralesional treatments have been proposed ([@CIT0028]) and therapy options in general have been summarized in a Cochrane review ([@CIT0009]). There is a need to further study the effects of intralesional treatments and of oral supplementation with zinc and other nutrients.

The many effects of zinc on wound healing in general have been reviewed ([@CIT0029]--[@CIT0031]). An important effect is exerted by zinc metalloenzymes involved in membrane stability and in the maturation of collagen during the proliferative and remodeling phases of wound healing. Many factors also affect the defense against parasites and how parasites can escape control. This may be due to a complex interaction between molecules released by the parasites to assure survival ([@CIT0032]) and the host immune response through release of oxidant molecules and increase of the concentration of pro-inflammatory cytokines ([@CIT0033]).

Biochemical markers {#S0004-S20003}
-------------------

In visceral leishmaniasis, other authors found a significantly increased level of CRP both before and after treatment compared to controls but then CRP decreased to similar levels as in controls at 90 days after treatment ([@CIT0034]--[@CIT0036]). In our study CRP was above the reference value 3.0 mg/L in nine patients at T0, nine patients at T2 and in six controls but the data did not show significant changes with time. The indicators of liver function before and after therapy plus supplementation in our study did not show significant changes between zinc-supplemented and placebo groups and also compared to their controls. Some authors reported increased levels of ASAT during treatment with antimony ([@CIT0037], [@CIT0038]), but other trials evaluating the tolerability of antimony and miltefosine reported no changes in hepatic parameters ([@CIT0039], [@CIT0040]).

Strengths and weaknesses {#S0004-S20004}
------------------------

This pilot study is the first one on the effects of oral zinc supplementation combined with intramuscular antimony therapy. A careful characterization of nutritional status in leishmaniasis patients was performed and compared with that in matched controls. Extensive documentation was made using clinical chemistry measurements and the study provides a possible model for performing intervention studies in Bolivia. In future studies, a larger number of patients should be included and additional biomarkers be used.

Conclusions {#S0005}
===========

Nutritional status in cutaneous leishmaniasis was essentially normal. No additional clinical benefit of zinc supplementation could be documented probably because antimony treatment alone had a high efficiency. Several changes were observed in different biochemical markers which could be attributed to other factors than a direct effect of zinc. There is a need to further study different treatments in leishmaniasis and the possible additive effects of zinc and other nutrients.

Supplementary Material
======================

###### Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment

###### 

Click here for additional data file.
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